1.Hyperpigmentation of the hard palate mucosa in a patient with chronic myeloid leukaemia taking imatinib.
Gian Paolo BOMBECCARI ; Umberto GARAGIOLA ; Francesco PALLOTTI ; Margherita ROSSI ; Massimo PORRINI ; Aldo Bruno GIANNÌ ; Francesco SPADARI
Maxillofacial Plastic and Reconstructive Surgery 2017;39(12):37-
BACKGROUND: Imatinib mesylate is an inhibitor of the tyrosine kinase Bcr–Abl and a first-line treatment for Philadelphia chromosome-positive chronic myeloid leukaemia (CML). Dermatological side effects include superficial oedema, pustular eruption, lichenoid reactions, erythroderma, and skin rash. Depigmentation of the skin and/or mucosa is uncommon, and hyperpigmentation is rare. CASE PRESENTATION: We present the case of a 63-year-old Caucasian male with widespread hyperpigmentation of the hard palate associated with a 9-year history of imatinib therapy to treat CML. He did not complain of any symptoms. Clinical examination did not reveal any abnormal pigmentation of the skin or other region of the oral mucosa. He did not smoke cigarettes or drink alcohol. His medication regimen was a proton pump inhibitor, a beta-blocker, cardioaspirin, atorvastatin, and imatinib 400 mg/day. Histopathologically, melanin and haemosiderin deposits were evident in the lamina propria. The lesion persisted, with no clinical change, through several follow-ups. We reviewed the literature to explore the possible relationship between oral hyperpigmentation and long-term imatinib mesylate treatment. CONCLUSIONS: We diagnosed oral pigmentation associated with imatinib intake based on the medical history and clinical features of the pigmented macules. Oral pigmentation may have a variety of causes, and differential diagnosis requires nodal analysis. Clinicians should be aware of possible oral mucosal hyperpigmentation in patients taking imatinib mesylate. Such pigmentation is benign and no treatment is needed, but surveillance is advisable.
Atorvastatin Calcium
;
Dermatitis, Exfoliative
;
Diagnosis, Differential
;
Exanthema
;
Follow-Up Studies
;
Humans
;
Hyperpigmentation*
;
Imatinib Mesylate*
;
Lichenoid Eruptions
;
Male
;
Melanins
;
Middle Aged
;
Mouth Mucosa
;
Mucous Membrane*
;
Palate, Hard*
;
Pigmentation
;
Protein-Tyrosine Kinases
;
Proton Pumps
;
Skin
;
Smoke
;
Tobacco Products
2.Diode laser surgery in the treatment of oral proliferative verrucous leukoplakia associated with HPV-16 infection
Gian Paolo BOMBECCARI ; Umberto GARAGIOLA ; Valentina CANDOTTO ; Francesco PALLOTTI ; Francesco CARINCI ; Aldo Bruno GIANNÌ ; Francesco SPADARI
Maxillofacial Plastic and Reconstructive Surgery 2018;40(1):16-
BACKGROUND: Proliferative verrucous leukoplakia (PVL) is an oral potentially malignant disorder, characterized by multifocal expression, progressive clinical evolution, and a high rate of malignant transformation. Evidence-based information regarding optimal PVL management is lacking, due to the paucity of data. The present report describes a case of PVL associated with HPV-16 infection and epithelial dysplasia treated by diode laser surgery, and the outcome of disease clinical remission over a 2-year follow-up period. CASE REPORT: A 61-year-old Caucasian male with oral verrucous hyperkeratosis presented for diagnosis. The lesions were localized on the maxillary gingiva and palatal alveolar ridge. Multiple biopsy specimens have been taken by mapping the keratotic lesion area. Microscopic examination was compatible with a diagnosis of PVL with focal mild dysplasia, localized in the right maxillary gingiva. Polymerase chain reaction (PCR) was done for human papillomavirus (HPV) detection which revealed presence of HPV DNA, and the genotype revealed HPV 16 in the sample. The PVL in the right gingival area was treated on an outpatient basis by excision with a diode laser. This approach resulted in good clinical response and decreased morbidity over a 2-year follow-up period. CONCLUSIONS: This case illustrates the benefit of a conservative approach by diode laser treatment than wide surgical excision for management of the PVL lesions associated with mild dysplasia and HPV-16 infection.
Alveolar Process
;
Biopsy
;
Diagnosis
;
DNA
;
Follow-Up Studies
;
Genotype
;
Gingiva
;
Human papillomavirus 16
;
Humans
;
Lasers, Semiconductor
;
Leukoplakia
;
Male
;
Middle Aged
;
Mouth Neoplasms
;
Outpatients
;
Polymerase Chain Reaction
3.Inhibin B: are modified ranges needed for orchiectomised testicular cancer patients?
Alessandra PETROZZI ; Francesco PALLOTTI ; Marianna PELLONI ; Antonella ANZUINI ; Antonio Francesco RADICIONI ; Andrea LENZI ; Donatella PAOLI ; Francesco LOMBARDO
Asian Journal of Andrology 2019;21(4):332-336
Inhibin B is a gonadal hormone that downregulates the pituitary production of follicle-stimulating hormone (FSH). In recent years, inhibin B has proved to be an excellent marker of spermatogenesis and even a predictive factor for the recovery of fertility in patients undergoing orchiectomy and antineoplastic treatments. We propose to study inhibin B levels in orchiectomised testicular cancer patients, in order to identify a minimum value representative of normal semen quality. This retrospective study evaluates hormonal and semen parameters of 290 normozoospermic patients attending the Laboratory of Seminology - Sperm Bank "Loredana Gandini" (Rome, Italy) for cryopreservation of seminal fluid following a diagnosis of testicular cancer (TC group) and 117 healthy, normozoospermic men as a control group (CTR group). The percentile distribution of gonadotropin and inhibin B values in the TC and CTR groups was analyzed. There was a statistically significant difference between the two groups in the levels of all hormones (P ≤ 0.001) and in all semen parameters (P < 0.05). About 20% of TC patients revealed inhibin B levels below the 5th percentile of CTR group, despite normozoospermia, and 31.4% had normal spermatogenesis in the presence of FSH values >95th percentile of CTR group. Orchiectomised patients for testicular cancer presented inhibin B levels lower than healthy patients, despite normozoospermia. Our study revealed the poor sensitivity of the current inhibin B reference range when applied to monorchidic patients, suggesting the need to establish more representative ranges to enable more appropriate counseling in relation to the patient's new endocrine condition.
Adult
;
Gonadotropins/blood*
;
Humans
;
Inhibins/blood*
;
Male
;
Orchiectomy
;
Reference Values
;
Testicular Neoplasms/surgery*
;
Testosterone/blood*
;
Young Adult